Pioneering founders, experienced leadership, and world-class advisors.

Leadership

Timothy Lu, M.D., Ph.D.

Co-founder and Chief Executive Officer

Timothy Lu, M.D., Ph.D.

Co-founder and Chief Executive Officer

Dr. Lu has served as our CEO since he co-founded Senti Bio in 2016. Since 2010, Dr. Lu has been an MIT faculty member in the departments of Biological Engineering and Electrical Engineering and Computer Science. In addition, Dr. Lu has been a co-founder and a Scientific Advisory Board member to a number of biotechnology and biopharmaceutical companies, including BiomX, Corvium, Eligo Bioscience, Engine Biosciences, Synlogic and Tango Therapeutics.

Dr. Lu earned his M.D. from Harvard Medical School and his Ph.D. in Electrical and Biomedical Engineering from Massachusetts Institute of Technology as part of the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program. Dr. Lu has extensive experience in the field of synthetic biology and has received numerous awards: NIH New Innovator Award, US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes and others.

Curt Herberts, M.B.S.

Chief Operating Officer

Curt Herberts, M.B.S.

Chief Operating Officer

Mr. Herberts has served as our Chief Operating Officer since 2021. As COO, he is responsible for core areas of the company including Program Leadership, People Operations, Corporate Development & Alliance Management as well as Legal & Intellectual Property. He has served as Treasurer since 2020, Secretary since 2018 and, from 2018 to 2021, Chief Financial Officer and Chief Business Officer. Mr. Herberts is a seasoned business leader with experience in corporate strategy, finance, business operations, commercialization and building high performing life science organizations. Prior to joining Senti Bio, Mr. Herberts held various positions at Sangamo Therapeutics, including as Senior Vice President and Chief Business Officer from 2016 to 2018, and Vice President and Head of Corporate Development from 2015 to 2016. Prior to Sangamo Therapeutics, Mr. Herberts served in various positions at Campbell Alliance Group (acquired by inVentiv Health).

Mr. Herberts earned his B.A. in Human Biology from Stanford University and his Master of Business and Science from the Keck Graduate Institute of Applied Life Sciences.

Deborah Knobelman, Ph.D.

Chief Financial Officer

Deborah Knobelman, Ph.D.

Chief Financial Officer

Dr. Knobelman has served as our CFO since joining Senti Bio in 2021. She brings over 20 years of experience on Wall Street and in the biopharma industry. Dr. Knobelman served in interim C-Suite roles for numerous life sciences companies and, prior to that, as CFO for GeneriCo Pharmaceuticals and CBO for Ampio Pharmaceuticals. In these positions, she led a wide range of public and private financing efforts, corporate strategy and finance, and investor relations activities. Earlier in her career, within Pfizer’s Primary Care business, she focused on commercial strategies for Primary Care products, and was involved in operational planning and budgeting. Dr. Knobelman began her career on Wall Street as an Equity Research Analyst covering Specialty Pharmaceuticals and Biotech for JPMorgan and Piper Jaffray, where she was named to Institutional Investor’s list of “Next Generation Analysts”.

Dr. Knobelman earned her PhD in Pharmacology from the University of Pennsylvania, and an AB with Distinction in Chemistry from Duke University.

Gary Lee, Ph.D.​

Chief Scientific Officer

Gary Lee, Ph.D.​

Chief Scientific Officer

Dr. Lee has served as our CSO since joining Senti Bio in 2018. Dr. Lee is a veteran biotech executive with over a decade of experience leading cell and gene therapy programs for human applications. Between 2005 and 2018 Dr. Lee held increasingly responsible scientific and leadership positions at Sangamo Therapeutics, including most recently Vice President of Cell Therapy.

Dr. Lee earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and his B.S. in Chemical Engineering from the California Institute of Technology.

Philip Lee, Ph.D.

Chief Technology Officer

Philip Lee, Ph.D.

Chief Technology Officer

Dr. Lee became our CTO in 2021 and is one of our co-founders. He served as our Chief Operating Officer from 2018 to 2021, as our President from 2016 to 2018, and as our Treasurer from 2016 to 2020. Prior to joining Senti Bio, Dr. Lee held various positions at MilliporeSigma, a division of Merck KGaA, including as the Head of Cell Culture Systems from 2014 to 2016 and Senior Manager of Science & Technology and New Business Initiatives Lead from 2012 to 2014. Dr. Lee co-founded CellASIC Corp. in 2004 and served as its Chief Executive Officer until it was acquired by Merck KGaA in 2012.

Dr. Lee earned his B.S. in Chemical Engineering and Biology from Massachusetts Institute of Technology and his Ph.D. in Bioengineering from the University of California, Berkeley and the University of California, San Francisco.

José Iglesias, M.D.

Chief Medical Advisor

José Iglesias, M.D.

Chief Medical Advisor

Dr. Iglesias has served as our consultant Chief Medical Advisor since 2020. Dr. Iglesias has served as Director at Apex Oncology Consulting since 2019. Prior to that, he served as Vice President, Transitional Medicine at Boston Biomedical from January 2019 to July 2019, as Oncology Consultant at Research Point Global from 2018 to 2019, as Vice President, Medical and Clinical Affairs at Apobiologix (a division of Apotex), from 2016 to 2018, as Chief Medical Officer at Biothera Pharmaceuticals from 2015 to 2016, as Chief Medical Officer at Bionomics Limited from 2012 to 2015, as Vice President, Clinical Development at Celgene Corporation from 2010 to 2012, as Chief Medical Officer and Vice President, Global Clinical Development at Abraxis BioScience from 2006 to 2010, as Medical Director at Amgen Canada from 2004 to 2006, and Oncology Medical Advisor and Associate Oncology Director at Eli Lilly and Company from 1994 to 2004.

Dr. Iglesias earned his M.D. from the University of the Republic in Montevideo, Uruguay. He completed his research fellowships at Duke University and the Weizmann Institute of Science and his post-doctoral fellowship at the University of Toronto.

Board of Directors

Timothy Lu, M.D., Ph.D.

Co-founder and Chief Executive Officer

Timothy Lu, M.D., Ph.D.

Co-founder and Chief Executive Officer

Dr. Lu has served as our CEO since he co-founded Senti Bio in 2016. Since 2010, Dr. Lu has been an MIT faculty member in the departments of Biological Engineering and Electrical Engineering and Computer Science. In addition, Dr. Lu has been a co-founder and a Scientific Advisory Board member to a number of biotechnology and biopharmaceutical companies, including BiomX, Corvium, Eligo Bioscience, Engine Biosciences, Synlogic and Tango Therapeutics.

Dr. Lu earned his M.D. from Harvard Medical School and his Ph.D. in Electrical and Biomedical Engineering from Massachusetts Institute of Technology as part of the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program. Dr. Lu has extensive experience in the field of synthetic biology and has received numerous awards: NIH New Innovator Award, US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes and others.

Lee Cooper

Director of Venture Investments, Leaps by Bayer

Lee Cooper

Director of Venture Investments, Leaps by Bayer

Lee Cooper has served as a member of our board of directors since 2020. Mr. Cooper has served as Senior Director of Venture Investments with Leaps by Bayer, an investment arm of Bayer AG since 2020. Prior to joining Leaps, Mr. Cooper was Entrepreneur-in-Residence with RA Capital Management from 2018 to 2019 and the founder of Enlight Biosciences, a private biotechnology company, from 2018 to 2019. Previously, Mr. Cooper served as Associate Director, Business Development & Corporate Finance for Moderna Therapeutics from 2015 to 2017.

Mr. Cooper currently serves on the board of directors of various private companies, including Triumvira Immunologics, and FutuRx. Mr. Cooper earned his A.B. in Religion and Public Policy from Dartmouth College and his J.D. and M.B.A. from Columbia University where he currently lectures on topics in biotechnology.

Brenda Cooperstone, M.D.

Chief Development Officer, Pfizer Rare Disease

Brenda Cooperstone, M.D.

Chief Development Officer, Pfizer Rare Disease

Dr. Cooperstone has served as a member of our board of directors since 2019. Dr. Cooperstone has held various leadership positions at Pfizer including as Senior Vice President since 2017, Chief Development Officer for Rare Disease in Global Product Development since 2016 and Head of Development for Rare Disease in Global Product Development from 2015 to 2016. Dr. Cooperstone started her career in the pharmaceutical industry at Wyeth Pharmaceuticals in 1999 and joined Pfizer in 2009.

Dr. Cooperstone earned her M.D. from McGill University, and completed her residency in pediatrics at the Montreal Children’s Hospital, her clinical fellowship in pediatric nephrology at Children’s Hospital of Philadelphia and a research fellowship at the University of Pennsylvania’s Renal Electrolyte division.

Ran Geng

Venture Investor, OrbiMed Advisors

Ran Geng

Venture Investor, OrbiMed Advisors

Ms. Geng has served as a member of our board of directors since 2021. Ms. Geng has served as a venture investor at OrbiMed Advisors since 2021. From 2017 to 2021, Ms. Geng served as a venture investor at Matrix Partners China focusing on biotechnology investments. Prior to Matrix Partners China, Ms. Geng was a consultant at ZS Associates from 2015 to 2017.

Ms. Geng earned her B.A. in Computational Biology from the University of Pennsylvania and her B.S.E. in Operations Management from the University of Pennsylvania Wharton Business School (Roy Vagelos Life Science Management Program).

Alex Kolicich

Partner, 8VC

Alex Kolicich

Partner, 8VC

Mr. Kolicich has served as a member of our board of directors since 2018. Mr. Kolicich is a founding partner of 8VC, a venture capital firm. Prior to joining 8VC in 2015, Mr. Kolicich was a Partner at Formation8 from 2014 to 2015. From 2012 to 2014, Mr. Kolicich worked as a Principal at Mithril Capital Management, a growth-stage venture capital fund.

Mr. Kolicich earned his B.SE in Software Engineering from University of Waterloo and his M.A. in Economics from University of Toronto.

Ed Mathers

Partner, NEA

Ed Mathers

Partner, NEA

Mr. Mathers has served as a member of our board of directors since 2016. Mr. Mathers has served as a General Partner at New Enterprise Associates (NEA), a private venture capital firm focusing on technology and healthcare investments, since 2019, and prior to that served as partner at NEA from 2008 to 2019. Prior to joining NEA, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune and led its venture capital subsidiary, MedImmune Ventures. Mr. Mathers currently serves on the board of directors of Affinia Therapeutics, Akouos, Amplyx Pharmaceuticals, Inozyme Pharma, MBX Biosciences, Mirum Pharmaceuticals, ObsEva SA, Reneo Pharmaceuticals, Rhythm Pharmaceuticals, Synlogic, (formerly known as Mirna Therapeutics) and Trevi Therapeutics.

Mr. Mathers earned his B.S. in Chemistry from North Carolina State University.

Scientific Advisory Board

James Collins, Ph.D.

Scientific Co-Founder

James Collins, Ph.D.

Scientific Co-Founder

Dr. Collins is the Termeer Professor of Medical Engineering and Science in the Institute for Medical Engineering and Science as well as Professor of Biological Engineering at Massachusetts Institute of Technology. He is one of the founders of the field of synthetic biology, and has the rare distinction of being elected to all three national academies—the National Academy of Sciences, National Academy of Engineering and National Academy of Medicine—and has received a number of major awards recognizing his work, including the Dickson Prize in Medicine. Dr. Collins has been a Rhodes Scholar, a Macarthur Fellow and a recipient of the NIH Pioneer Award. In addition to his role as a faculty member at MIT, Dr. Collins is a Core Faculty member of the Wyss Institute at Harvard and an Institute Member of the Broad Institute of MIT and Harvard. Dr. Collins is a co-founder of EnBiotix, Synlogic and Sherlock Biosciences.

Dr. Collins earned his Ph.D. in Medical Engineering from the University of Oxford, and an A.B. in Physics from the College of the Holy Cross.

Wilson Wong, Ph.D.

Scientific Co-Founder

Wilson Wong, Ph.D.

Scientific Co-Founder

Dr. Wong is an Assistant Professor at Boston University. He is an expert in immune cell engineering and synthetic biology for therapeutic applications. Dr. Wong’s research has been published in numerous high-impact journals including Nature, Nature Biotechnology, Cell and PNAS. Dr. Wong has been recognized with multiple early academic career awards, including the NIH New Innovator Award, the ACS Synthetic Biology Young Investigator Award and the NSF CAREER Award.

Dr. Wong earned his B.S. in Chemical Engineering from the University of California, Berkeley. He earned his Ph.D. in Chemical and Biomolecular Engineering from the University of California, Los Angeles. Dr. Wong completed his postdoctoral studies in the laboratory of Professor Wendell Lim at University of California, San Francisco.

Michael Andreeff, M.D., Ph. D.

Clinical Advisor

Michael Andreeff, M.D., Ph. D.

Clinical Advisor

Dr. Andreeff is a Professor of Medicine and holds the Paul and Mary Haas Chair in Genetics at the University of Texas MD Anderson Cancer Center. He has worked extensively on drug resistance in hematopoietic malignancies, such as acute myelogenous leukemia (AML), and developed or co-developed several new therapeutic agents.

Dr. Andreeff earned his M.D. and Ph.D. from the University of Heidelberg Medical School, and additional training and faculty appointments at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York in the Departments of Pathology and Leukemia.

Lawrence Fong, M.D.

Clinical Advisor

Lawrence Fong, M.D.

Clinical Advisor

Dr. Fong is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at the University of California, San Francisco. Dr. Fong is a physician-scientist in UCSF’s Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH funded research lab. He has been focused on cancer immunotherapy for two decades and has been involved in both preclinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors.

Dr. Fong earned his M.D. from Stanford University, completed a residency in internal medicine at the University of Washington and completed an oncology fellowship at Stanford Medicine. He earned his B.A. from Columbia University.

Martin Fussenegger, Ph.D.

Technical Advisor

Martin Fussenegger, Ph.D.

Technical Advisor

Dr. Fussenegger is a Professor of Biotechnology and Bioengineering at ETH Zurich. He is a pioneer in therapeutic synthetic biology and a member of the National Academy of Engineering, and is the recipient of numerous honors including the AIChE Bailey Award and the Merck Cell Culture Engineering Award.

Dr. Fussenegger graduated with Werner Arber at the Biocenter of the University of Basel, earned his Ph.D. in Medical Microbiology from the Max Planck Institute of Biology, and completed his postdoctoral studies at the Max Planck Institute of Infection Biology.

Ahmad (Mo) Khalil, Ph.D.

Technical Advisor

Ahmad (Mo) Khalil, Ph.D.

Technical Advisor

Dr. Khalil is an Assistant Professor of Biomedical Engineering and the Associate Director of the Biological Design Center at Boston University, and a Visiting Scholar at the Wyss Institute at Harvard University. Dr. Khalil is an expert in transcription factor engineering for mammalian synthetic biology applications. He is recipient of awards including the Presidential Early Career Award for Scientists and Engineers (PECASE), NIH New Innovator Award, NSF CAREER Award, DARPA Young Faculty Award and a Hartwell Foundation Biomedical Research Award.

Dr. Khalil earned his M.S. and Ph.D. in Mechanical Engineering from Massachusetts Institute of Technology. He earned his B.S. in Mechanical Engineering from Stanford University.

Our investors and partners

Our industry-leading partners share our vision of synthetic biology becoming an important pillar in next-generation cell and gene therapy.  

View partnering